| Year |
Citation |
Score |
| 2014 |
Pericolini E, Gabrielli E, Alunno A, Bartoloni Bocci E, Perito S, Chow SK, Cenci E, Casadevall A, Gerli R, Vecchiarelli A. Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan. Plos One. 9: e111163. PMID 25338013 DOI: 10.1371/Journal.Pone.0111163 |
0.402 |
|
| 2014 |
Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. The Journal of Clinical Investigation. 124: 725-9. PMID 24401277 DOI: 10.1172/Jci72676 |
0.669 |
|
| 2014 |
Alunno A, Pericolini E, Gabrielli E, Bistoni O, Caterbi S, Bartoloni E, Terenzi R, Valentini E, La Paglia G, Chow S, Casadevall A, Vecchiarelli A, Gerli R. A6.2 Purified microbial capsular polysaccharide Galactoxylomannan (GalXM) inhibits the effector T lymphocyte arm and potentiates the regulatory counterpart in rheumatoid arthritis Annals of the Rheumatic Diseases. 73: A71.1-A71. DOI: 10.1136/Annrheumdis-2013-205124.162 |
0.401 |
|
| 2013 |
Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, Casadevall A. Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host & Microbe. 13: 417-28. PMID 23601104 DOI: 10.1016/J.Chom.2013.03.001 |
0.62 |
|
| 2013 |
Pohl MA, Rivera J, Nakouzi A, Chow SK, Casadevall A. Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infection and Immunity. 81: 1880-8. PMID 23509144 DOI: 10.1128/Iai.01328-12 |
0.691 |
|
| 2013 |
Pericolini E, Alunno A, Gabrielli E, Bartoloni E, Cenci E, Chow SK, Bistoni G, Casadevall A, Gerli R, Vecchiarelli A. The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. Plos One. 8: e53336. PMID 23308194 DOI: 10.1371/Journal.Pone.0053336 |
0.398 |
|
| 2012 |
Chow SK, Casadevall A. Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins. 4: 430-54. PMID 22822456 DOI: 10.3390/Toxins4060430 |
0.622 |
|
| 2011 |
Vecchiarelli A, Pericolini E, Gabrielli E, Chow SK, Bistoni F, Cenci E, Casadevall A. Cryptococcus neoformans galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. Immunotherapy. 3: 997-1005. PMID 21843086 DOI: 10.2217/Imt.11.86 |
0.516 |
|
| 2011 |
Eisenman HC, Chow SK, Tsé KK, McClelland EE, Casadevall A. The effect of L-DOPA on Cryptococcus neoformans growth and gene expression. Virulence. 2: 329-36. PMID 21705857 DOI: 10.4161/Viru.2.4.16136 |
0.378 |
|
| 2011 |
Chow SK, Casadevall A. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine. 29: 1891-8. PMID 21238568 DOI: 10.1016/J.Vaccine.2010.12.134 |
0.589 |
|
| 2010 |
Jesus MD, Nicola AM, Chow SK, Lee IR, Nong S, Specht CA, Levitz SM, Casadevall A. Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence. 1: 500-8. PMID 21178496 DOI: 10.4161/Viru.1.6.13451 |
0.56 |
|
| 2010 |
Abboud N, Chow SK, Saylor C, Janda A, Ravetch JV, Scharff MD, Casadevall A. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. The Journal of Experimental Medicine. 207: 2395-405. PMID 20921285 DOI: 10.1084/Jem.20100995 |
0.557 |
|
| 2010 |
Pericolini E, Gabrielli E, Bistoni G, Cenci E, Perito S, Chow SK, Riuzzi F, Donato R, Casadevall A, Vecchiarelli A. Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. Plos One. 5: e12720. PMID 20856869 DOI: 10.1371/Journal.Pone.0012720 |
0.413 |
|
| 2010 |
De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryotic Cell. 9: 1018-28. PMID 20061411 DOI: 10.1128/Ec.00268-09 |
0.625 |
|
| Show low-probability matches. |